Arcutis Biotherapeutics, Inc. vs Pfizer, Inc. — Stock Comparison
Arcutis Biotherapeutics, Inc. (ARQT) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Arcutis Biotherapeutics, Inc. narrowly edges Pfizer, Inc. on Q·Score (6.7 vs 6.4 out of 10), led by Growth (7.7 vs 5.1) and Sentiment (7.9 vs 5.3). Pfizer, Inc. scores higher on Quality, reflecting stronger profitability and returns. Analyst consensus targets imply greater upside for ARQT (+32.1%) than for PFE (+15.8%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $34.63 is 32% above current price.
⚠ currently unprofitable (-1% margin).
Forward P/E of 8.9× is low relative to sector peers.
⚠ earnings contracting 10% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ARQT vs PFE: which stock scores better overall?
Based on Q·Score, Arcutis Biotherapeutics, Inc. (ARQT) scores 6.7/10 versus Pfizer, Inc. (PFE) at 6.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ARQT or PFE?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Growth (7.7/10 vs 5.1/10). Arcutis Biotherapeutics, Inc. reports revenue growth (60.1% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ARQT or PFE more attractively valued?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Valuation (8.1/10 vs 7.7/10). ARQT trades at 22.7× P/E versus PFE at 8.9×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ARQT vs PFE?
There are 8 analysts covering ARQT with a consensus price target of $34.63, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ARQT or PFE?
Pfizer, Inc. (PFE) scores higher on Quality (6.4/10 vs 3.5/10). Net profit margin: ARQT at -0.6%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ARQT or PFE?
Arcutis Biotherapeutics, Inc. (ARQT) scores higher on Financial Health (7.4/10 vs 7/10). Market beta: ARQT at 1.52, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ARQT and PFE?
Arcutis Biotherapeutics, Inc. (ARQT) has a market capitalisation of $3.3B, while Pfizer, Inc. (PFE) has a market cap of $143.7B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ARQT or PFE pay dividends?
ARQT does not currently pay a dividend, while PFE pays a dividend yield of 6.61%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →